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24-month survival rate of the SLN-T lymphocyte group 
was significantly higher than that of the control group: 
55.6 versus 17.5 % (p = 0.02). The median overall survival 
of the SLN-T lymphocyte and control groups was 28 and 
14 months, respectively. Our study showed that adjuvant 
SLN-T lymphocyte immunotherapy is feasible and safe for 
postoperative CRC patients. Additionally, this therapy may 
improve the long-term survival of metastatic CRC. Further 
investigation of the clinical efficacy and anti-tumor immu-
nity is warranted.
Keywords Colorectal cancer · Adoptive immunotherapy · 
Sentinel lymph node · T lymphocytes · Phase I/II study
Abbreviations
ACT  Adoptive cell transfusion
ALP  Alkaline phosphatase
ALT  Alanine aminotransferase
APC  Antigen-presenting cell
AST  Aspartate transaminase
CEA  Carcinoma embryonic antigen
CLTA-4  Cytotoxic T lymphocyte-associated antigen-4
CRC  Colorectal cancer
ECOG  Eastern Cooperative Oncology Group
ELISPOT  Enzyme-linked immunospot
EpCAM  Epithelial cell adhesion molecule
5-FU  5-Fluorouracil
IFN-γ  Interferon gamma
mAbs  Monoclonal antibodies
mCRC  Metastatic colorectal cancer
NK  Natural killer
OS  Overall survival
PBL  Peripheral blood
PBMCs  Peripheral blood mononuclear cells
PD-1  Programmed cell death protein 1
Abstract Although the development of multi-discipli-
nary management has improved the survival of colorectal 
cancer (CRC), the prognosis of metastatic CRC patients 
remains poor. Accumulating evidence has demonstrated 
that immunotherapy with cancer vaccines and adoptive T 
cell transfusions may improve outcomes as an adjuvant to 
current standard CRC treatment. In this phase I/II study, 71 
CRC patients who underwent radical surgery (stage I–III, 
n = 46) or palliative surgery (stage IV with non-resecta-
ble synchronous metastases, n = 25) were included. In the 
first part of this study, sentinel lymph nodes (SLNs) were 
intraoperatively identified in 55 patients (46 with stage I–
III CRC and 9 with stage IV CRC). SLN-T lymphocytes 
were expanded ex vivo for a median of 28.5 days (range 
23–33 days). Thereafter, a median of 153 × 106 cells 
(range 20.7–639.0 × 106) were transfused. No treatment-
related toxicity was observed. In the second part of this 
study, the stage IV patients were routinely followed. The 
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RFA  Radiofrequency ablation
SLNs  Sentinel lymph nodes
TACE  Transcatheter arterial chemoembolization
TCM  Central memory T cell
TDLNs  Tumor-draining lymph nodes
TEM  Effector memory T cell
TILs  Tumor-infiltrating lymphocytes
Tregs  Regulatory T cells
TTD  Terminally differentiated T cell
Introduction
Colorectal cancer (CRC), one of the leading causes of 
cancer-related death, constitutes a major health problem 
worldwide. The CRC mortality rate varies by country and 
is affected by several factors, including the local incidence, 
the stage at diagnosis, the presence of factors associated 
with poor prognosis and the effectiveness of treatments 
[1]. With the development of multi-disciplinary treatment 
approaches and noninvasive screening, the 5-year survival 
rate of CRC improved from 58.0 to 64.9 % from 2003 to 
2009 in the USA [2]. Although improved survival has 
been observed in many countries, a significant percentage 
(>20–25 %) of patients exhibit distant metastases at the 
time of diagnosis [3]. Among patients (stage I–III) who are 
eligible to receive curative resection, approximately 35 % 
develop tumor recurrence with eventual distant metastases 
during the disease course, especially within the first 3 years 
post-surgery [4]. The 5-year survival rate of non-resectable 
metastatic CRC (mCRC) is <12.5 % [2]. Therefore, there 
remains a significant need to effectively prevent tumor 
recurrence and to further improve the treatment outcomes 
for non-resectable mCRC.
During the last decade, cancer immunotherapy has 
emerged as a promising method of treating cancer [5, 6]. 
Growing clinical evidence has demonstrated that immune-
based therapies are efficacious against certain types of 
cancer [7, 8]. In CRC, immunotherapy using cancer vac-
cines or adoptive T cell transfusion has exhibited promising 
therapeutic efficacy in prolonging progression-free survival 
and long-term survival, and immunotherapy may improve 
outcomes as an adjuvant to current standard treatment regi-
mens [9–16].
Peripheral blood mononuclear cells (PBMCs) and 
tumor-infiltrating lymphocytes (TILs) are the most com-
monly reported starting materials for adoptive T cell 
immunotherapy. The expansion of cytotoxic T cells from 
tumor-draining lymph nodes (TDLNs) was first reported 
by Yanagawa [17]. Subsequent studies demonstrated that 
the TDLNs serve as a potential source of tumor-reactive 
T cells [15, 18–20]. To identify the optimal location to 
obtain tumor-reactive T cells for adoptive immunotherapy 
for CRC, tumor reactivity was compared between PBMCs, 
TILs and SLN-T cells from CRC patients [21]. SLN-T 
cells were found to represent an enriched source of tumor-
reactive lymphocytes that proliferate upon stimulation with 
autologous tumor antigen.
In this phase I/II study, we evaluated the feasibility, 
toxicity and clinical effect of SLN-T cell-based adjuvant 
immunotherapy in postoperative CRC patients.
Materials and methods
Patients
Stage I–IV CRC patients were recruited at the Department 
of Colorectal Surgery of the Affiliated Hospital of Gui-
yang Medical College and the Department of Gastrointes-
tinal Surgery of the Affiliated Cancer Hospital of Guiyang 
Medical College. Patients were selected according to the 
following criteria: age ≥18 years; histologically confirmed 
CRC with a life expectancy ≥3 months; patients (stage I–
III) who underwent radical surgery; patients (stage IV) 
with synchronous metastases who underwent palliative sur-
gery; and Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. Patients were excluded if they 
had received neo-adjuvant chemo (radio) therapy before 
surgery, had a history of autoimmune disease or immuno-
deficiency syndrome, were currently treated with steroids 
or exhibited contraindications of leukapheresis.
The study protocol was reviewed and approved by the 
hospital ethical committee. All patients provided written 
informed consent before entering the study.
Study design
This phase I/II study consisted of two parts. In the first 
part, the feasibility and safety of SLN-T cell transfusion 
in an adjuvant setting were studied. The SLNs were intra-
operatively identified using patent blue injections. Patients 
who demonstrated successful ex vivo expansion of SLN-T 
cells received intravenous cell transfusion. Patients with 
(1) stage II (along with high-risk factors), (2) stage III 
or (3) stage IV disease received standard 5-fluorouracil 
(5-FU)-based chemotherapy within 8 weeks after surgery. 
The SLN-T cells were transfused 7 days after the first 
cycle of chemotherapy; the second phase of the study was 
designed to explore the potential efficacy of SLN-T cell 
immunotherapy as a supplement to standard chemother-
apy in stage IV patients after palliative surgery. The OS 
of these patients was followed from the day of enrollment 
until death.
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Intraoperative identification of SLNs
The SLNs were identified as described previously [22]. In 
brief, 1 ml of patent blue dye was injected under the ser-
osa surrounding the primary tumor. Within 5 min, the SLN 
stained blue. The SLN was excised and cut in half; one 
half was subjected to flow cytometry analysis and ex vivo 
expansion, and the remaining half was used for routine his-
topathological examination.
Immunological evaluation of SLN‑derived lymphocytes
Single-cell suspensions from SLNs and tumor tissue were 
obtained immediately after surgery by applying gentle pres-
sure using a loose-fit glass homogenizer as described by 
Marits [21]. PBMCs were purified by Ficoll-Paque (Amer-
sham). For phenotypic analysis of the lymphocytes from 
SLNs, TILs and PBMCs, fluorescent-labeled monoclonal 
antibodies (mAbs) against CD45, CD3, CD4, CD8, CD16, 
CD56, CD19, CD69, CD25, CD127, CD45RA and CCR7 
(Beckman Coulter) were used. Cells were incubated in the 
presence of mAbs according to the manufacturer’s recom-
mendations for 20 min at room temperature (18–25 °C) and 
protected from light. After incubation, the cell suspensions 
were washed with phosphate-buffered saline (PBS), and the 
cell pellets were resuspended in 0.5 ml of PBS for analysis. 
Samples were further analyzed using a FC500 flow cytome-
ter (Beckman Coulter). At least 50,000 total events were col-
lected and analyzed using CXP software (Beckman Coulter).
An enzyme-linked immunospot (ELISPOT) assay kit 
(Mabtech AB, Sweden) was used to evaluate the antigen-
specific T cells by measuring the release of interferon 
gamma (IFN-γ). Lymphocytes (1 × 105/well) isolated from 
SLNs and PBMCs were seeded in 96-well plates that were 
pre-coated with an anti-human IFN-γ antibody in triplicate 
and incubated with autologous tumor lysates or an anti-
CD3 mAb. After 48 h of incubation, the assay was devel-
oped according to the standard protocol. The membranes 
were air-dried, and the spots in each well were subjected 
to automated evaluation using the AID FluoroSpot Reader 
System (Autoimmun Diagnostika GmbH, Germany).
Ex vivo expansion of SLN‑T cells
Single-cell suspensions obtained from SLNs were resuspended 
in X-VIVO™ 15 serum-free cell culture medium (LONZA) at 
a density of 4 × 106 cells/ml in the presence of 1000 IU/ml 
recombinant human interleukin-2 (Shuanglu, China). These 
cells were plated in flasks or plates and maintained in a humid-
ified atmosphere containing 5 % CO2 at 37 °C. The autolo-
gous tumor lysate was added to the initial culture at a dilution 
of 1/100 (v/v) as described previously [15]. To induce highly 
tumor-specific SLN-T cells, re-stimulation was performed 
by adding autologous tumor lysate together with irradiated 
autologous PBMCs during SLN-T cell cultures. One week 
before transfusion, 5 ml of culture medium was removed for 
a bacterial and fungal contamination test using BACTEC 9120 
(Becton–Dickinson), and the endotoxin levels were measured 
based on the Limulus reaction. On the day of transfusion, 
these assays were repeated to detect any bacterial, fungal or 
endotoxin contamination. The lymphocyte subsets of SLN-T 
cells were analyzed. Furthermore, 1 × 106 cells were used for 
flow cytometry analysis of the tumor surface marker epithelial 
cell adhesion molecule (EpCAM) to exclude the presence of 
tumor cells.
Adoptive transfusion of SLN‑T cells and toxicity 
evaluation
The final SLN-T cells were harvested, washed twice in saline 
solution and transferred to a sterile plastic bag containing 
200 ml of saline solution and 1 % human serum albumin (CSL 
Behring GmbH, Germany). The cells were intravenously 
transfused over a 60-min interval according to the blood trans-
fusion guidelines of the hospital. Transfusion-related toxicity 
was assessed post-cell transfusion using the Common Termi-
nology Criteria for Adverse Events (CTCAE) 3.0 criteria.
Follow‑up of stage IV patients
The stage IV CRC patients were followed every 3 months 
in the first year and every 6 months beginning in the sec-
ond year. The disease status was assessed based on physi-
cal examination, the serum level of carcinoma embryonic 
antigen (CEA), chest CT, abdominal CT and colonoscopy.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
version 5.0 (GraphPad Software, Inc, San Diego, CA). 
Changes in surface markers and INF-γ release between 
the groups were assessed using Student’s t test or one-way 
ANOVA. Categorical variables were compared using the 
Chi-squared and Fisher’s exact tests. Kaplan–Meier curves 
were used to assess the influence of SLN-T cell immuno-
therapy on OS. The significance of the difference between 
two groups was assessed using the log-rank test. All results 
were considered to be significant at p < 0.05.
Results
Patient characteristics
Eighty-seven CRC patients were enrolled between June 
2010 and August 2013. Among them, 71 patients (stage 
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I–IV) were included in the SLN-T immunotherapy group, 
and the remaining 16 stage IV patients, who received pal-
liative surgery and standard chemotherapy, served as con-
trols. Because of the unsuccessful expansion of SLN-T 
cells from 16 patients in the SLN-T immunotherapy group, 
55 patients (46 stage I–III and 9 stage IV, as shown in 
Table 1) received SLN-T cell transfusion. Together with the 
16 stage IV CRC patients in the control group, a final total 
number of 71 CRC patients (46 stage I–III and 25 stage IV) 
were included for analysis in this study (Fig. 1).
The characteristics of the 25 stage IV CRC patients in the 
control group (n = 16) and the SLN-T immunotherapy group 
(n = 9) are summarized in Table 2. The SLN-T and control 
groups did not significantly differ with respect to age, sex, 
histological grade, the characteristics of the primary tumor 
or the lymph nodes, distant metastasis, the levels of CEA, 
hemoglobin, alkaline phosphatase (ALP), bilirubin, creati-
nine, albumin, alanine aminotransferase (ALT) or aspartate 
transaminase (AST), surgical intervention for the primary 
and metastatic tumors or the number of cycles of chemo-
therapy received post-operation. Six patients (37.5 %) in the 
control group received second-line treatment with an anti-
EGFR/VEGF-targeted agent, whereas none of the patients in 
the SLN-T group received this treatment (p = 0.06).
SLN identification and phenotypic analysis 
of lymphocyte subtypes
The SLNs were intraoperatively identified by injecting pat-
ent blue in the circumference of the tumor (Fig. 2a). One to 
three identified SLNs were collected into a 15-ml tube con-
taining pre-chilled X-VIVO™ 15 medium. The lymphocyte 
subtypes present in the SLN and corresponding peripheral 
blood (PBL) were determined by flow cytometry. A signifi-
cant difference in lymphocyte composition was observed 
between the SLNs and the PBL. The proportions of CD19+ 
B lymphocytes (p < 0.0001) and CD3+CD4+ T lympho-
cytes (p = 0.031) were markedly higher in SLNs, whereas 
the cytotoxic CD3+CD8+ T lymphocytes (p < 0.0001) and 
CD16+CD56+ natural killer (NK) cells (p < 0.0001) were 
significantly less prevalent in SLNs. As a consequence of 
the increased proportion of CD3+CD4+ T lymphocytes and 
the decreased proportion of CD3+CD8+ T lymphocytes, 
the CD4/CD8 ratio was dramatically higher in SLNs than 
in the PBL (p < 0.0001) (Fig. 2b).
Given the elevated proportion of CD3+CD4+ T lympho-
cytes observed in SLNs, we further examined the presence of 
regulatory T cells (Tregs) in the SLNs and corresponding PBL 
by identifying the CD4+CD25hiCD127low/− cells (Fig. 2c). 
The proportion of circulating CD4+CD25hiCD127low/− Tregs 
in the PBL was significantly higher in CRC patients than in 
healthy controls (p < 0.0001). The distribution of circulat-
ing Tregs in the PBL or in SLNs did not significantly dif-
fer between patients with tumor-free lymph nodes (N0) and 
those with metastatic lymph nodes (N1 or N2) (Fig. 2c).
SLNs contain tumor‑reactive T cells
To evaluate the activation status of lymphocytes in SLNs, 
TILs and PBL, the expression of the very early activation 
marker CD69 was investigated [21]. The SLNs contained 
a significantly higher proportion of activated CD3+CD69+ 
Table 1  Characteristics of patients who received SLN-T cell transfu-
sion
Patient Stage I Stage II Stage III Stage IV
Number 
(n = 55)
5 20 21 9
Gender
 M 3 16 13 5
 F 2 4 8 4
Age (median, 
years)
65 (62–69) 60.5 (37–76) 58.8 (32–73) 56 (45–74)
Primary sites of disease
 Colon 2 13 11 7
 Rectum 3 7 10 2
SLN T-lymphocyte 
immunotherapy
(stage IV, n=9) 
Control





Feasibility and safety evaluation of SLN 
T-lymphocytes in stage I-IV patients
(n=55) 
Part II
Potential efficacy of SLN T-lymphocytes 





Stage I-III (n=46) 
Palliative surgery
Stage IV with synchronous 
metastases (n=25) 
Fig. 1  Study design. Patients with stage I–III CRC undergoing radi-
cal surgery and patients with stage IV CRC undergoing palliative 
resection were included in this study. In part I, the feasibility and 
safety of SLN-T cell as an adjuvant treatment were evaluated in 55 
postoperative stage I–IV patients. In part II, the efficacy of SLN-T 
cell treatment was further evaluated by measuring overall survival 
(OS) in 25 stage IV CRC patients
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Table 2  Baseline 
characteristics of stage IV CRC 
patients
Characteristic Control (n = 16) SLN-T (n = 9) Total (n = 25) p
Median age (range), years 51 (32.0–76.0) 56.0 (45.0–74.0) 55.0 (32.0–76.0) 0.205
Sex
 Female 3 (18.8) 4 (44.4) 7 (28.0) 0.21
 Male 13 (81.2) 5 (55.6) 18 (72.0)
Primary sites of disease
 Colon 10 (62.5) 7 (77.8) 17 (68.0) 0.66
 Rectum 6 (37.5) 2 (22.2) 8 (32.0)
Histology
 High (grade 3–4) 11 (68.8) 6 (66.7) 17 (68.0) 1.00
 Low (grade 1–2) 5 (31.2) 3 (33.3) 8 (32.0)
Primary tumor (T)
 T1/T2 0 (0.0) 0 (0.0) 0 (0.0) 0.235
 T3 9 (56.3) 8 (88.9) 17 (68.0)
 T4 6 (37.5) 1 (11.1) 7 (28.0)
 Tx 1 (6.2) 0 (0.0) 1 (4.0)
Lymph node involvement (N)
 N0 2 (12.5) 3 (33.3) 5 (20.0) 0.09
 N1 6 (37.5) 4 (44.4) 10 (40.0)
 N2 1 (6.3) 2 (22.2) 3 (12.0)
 Nx 7 (43.7) 0 (0.0) 7 (28.0)
Distant metastasis (M)
 M1a 10 (62.5) 2 (22.2) 12 (48.0) 0.97
 M1b 6 (37.5) 7 (77.8) 13 (52.0)
CEA
 Normal 2 (12.5) 3 (33.3) 5 (20.0) 0.31
 Abnormal 14 (87.5) 6 (66.7) 20 (80.0)
Hemoglobin
 Normal 7 (43.8) 6 (66.7) 13 (52.0) 0.41
 Abnormal 9 (56.2) 3 (33.3) 12 (48.0)
ALP
 Normal 13 (81.3) 8 (88.9) 21 (84.0) 1.00
 Abnormal 3 (18.7) 1 (11.1) 4 (16.0)
Bilirubin
 Normal 14 (87.5) 9 (100.0) 23 (92.0) 0.52
 Abnormal 2 (12.5) 0 (0.0) 2 (8.0)
Creatinine
 Normal 13 (81.3) 8 (88.9) 21 (84.0) 1.00
 Abnormal 3 (18.7) 1 (11.1) 4 (16.0)
Albumin
 Normal 12 (75.0) 8 (88.9) 20 (80.0) 0.62
 Abnormal 4 (25.0) 1 (11.1) 5 (20.0)
ALT
 Normal 13 (81.3) 7 (77.8) 20 (80.0) 1.00
 Abnormal 3 (18.7) 2 (22.2) 5 (20.0)
AST
 Normal 14 (87.5) 9 (100.0) 23 (92.0) 0.52
 Abnormal 2 (12.5) 0 (0.0) 2 (8.0)
Surgical management
Primary tumor resection 9 (56.3) 9 (100.0) 18 (72.0)
Metastatic tumor resection 0 (0.0) 0 (0.0) 0 (0.0)
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ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate transaminase, CEA carcinoembry-
onic antigen
Table 2  continued Characteristic Control (n = 16) SLN-T (n = 9) Total (n = 25) p
Cycles of chemo
 <4 8 (50.0) 4 (44.4) 12 (48.0) 1.00
 ≥4 8 (50.0) 5 (55.6) 13 (52.0)
Anti-EGFR/VEGF therapy
 Yes 6 (37.5) 0 (0.0) 6 (24.0) 0.06
 No 10 (62.5) 9 (100.0) 19 (76.0)
Fig. 2  Identification of SLN and lymphocyte populations in the SLN 
and corresponding PBL of CRC patients. a Within 5 min of intra-
operative injection of patent blue dye around the primary tumor, the 
SLN stained blue. b The proportion of CD19+, CD3+, CD3+CD4+, 
CD3+CD8+, CD16+CD56+ cells, and the CD4/CD8 ratio in SLN and 
corresponding PBL. c The proportion of CD4+CD25hiCD127low/− 
Tregs in PBL and SLNs of patients with tumor-free lymph node 
(N = 0) and those with metastatic lymph node (N = 1 or 2) deter-
mined by flow cytometry. d The changes of CD4+CD25hiCD127low/− 
Tregs in PBL of stage III CRC patients (n = 3) after surgery and sys-
tematic 5-FU-based chemotherapy
1089Cancer Immunol Immunother (2015) 64:1083–1093 
1 3
(p = 0.0003) and CD4+CD69+ (p < 0.0001) T lymphocytes 
compared to TILs. In the PBL, no activation of T lympho-
cytes was detected (Fig. 3a).
To evaluate the tumor-specific responses of the SLN 
lymphocytes to autologous tumor lysate, we performed 
IFN-γ ELISPOT assays (Fig. 3b). Significantly enhanced 
IFN-γ release in response to autologous tumor antigens 
was observed in SLN-T lymphocytes (p = 0.0015). Inter-
estingly, harvested SLNs not treated with autologous tumor 
antigen showed a low level of spontaneous IFN-γ secretion, 
suggesting the initiation of T lymphocyte activation in 
the SLN. However, in the PBL, no tumor-reactive IFN-γ-
secreting lymphocytes were observed when stimulated with 
autologous tumor antigens (Fig. 3b).
Profiles of surface markers in ex vivo‑expanded SLN‑T 
cells
Ex vivo expansion of SLN-T cells was performed for 
a median of 28.5 days (range 23–33 days) in culture. 
Fig. 3  Phenotype and functional activity of ex vivo-expanded SLN-T 
cells and the Kaplan–Meier curves of stage IV patients. a The pro-
portion of CD3+CD69+, CD4+CD69+T lymphocytes in SLNs, PBL 
and TILs. b IFN-γ ELISPOT assays were performed to determine the 
tumor-specific response of SLN lymphocytes and corresponding PBL 
lymphocytes. c Ex vivo expansion of SLN-T cells resulted in poly-
clonal expansion of CD3+CD8+ and CD3+CD4+ cells and a dimin-
ished CD19+ B cell population. d At the end of ex vivo expansion, 
the memory phenotype with CCR7 and CD45RA was characterized 
by flow cytometry (n = 17). e Kaplan–Meier curves for 33-month 
survival of stage IV CRC patients
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The cultures of SLN-T cells proliferated in response to 
autologous tumor antigens, and the median cell num-
ber reached 153.0 × 106 (range 20.7–639.0 × 106) for 
transfusion.
A comparison of surface marker expression between 
the starting culture and the ending culture (Fig. 3c) 
revealed that the percentage of CD19+ B lympho-
cytes significantly decreased from 25.8 ± 14.9 % to 
1.5 ± 4.7 % (p < 0.0001). Simultaneously, a substan-
tial increase in the percentage of CD3+ T cells from 
69.9 ± 14.2 % to 86.0 ± 11.8 % (p < 0.0001) was 
observed after ex vivo expansion. The expansion pro-
tocol resulted in alterations in the percentages of 
CD3+CD8+ cytotoxic T lymphocytes from 15.4 ± 6.9 % 
to 36.7 ± 14.6 % (p < 0.0001), CD3+CD4+ lympho-
cytes from 50.1 ± 10.7 % to 42.2 ± 16.9 % (p = 0.004) 
and CD16+CD56+ NK cells from 1.5 ± 3.3 % to 
12.0 ± 10.6 % (p < 0.0001) (data not shown). We next 
determined the memory phenotype using the lymph 
node-homing chemokine receptor marker CCR7 together 
with CD45RA to further characterize the phenotype and 
the function of tumor-specific SLN-T cells. At the end 
of ex vivo expansion, the majority of the cultured cells 
exhibited a differentiated effector T (CCR7−CD45RA+) 
or central memory T (CCR7+CD45RA−) pheno-
type, whereas the proportion of the effector memory 
T (CCR7−CD45RA−) subpopulation had dramatically 
decreased (Fig. 3d). This result demonstrated the pre-
dominant expansion of activated tumor-specific effector 
and central memory T cells.
Treatment‑related toxicity in stage I–IV patients 
and survival of stage IV patients
The SLN-T cell transfusion-related toxicity in 55 patients 
(46 stage I–III and 9 stage IV) is summarized in Table 3. 
No significant induction of toxicity was observed after 
intravenous administration of SLN-T cells.
Because of their palliative situation, the stage IV patients 
in both the SLN-T immunotherapy and control groups 
received treatments deemed necessary to provide adequate 
supportive care. During follow-up, the patients exhibiting 
disease progression received second-line chemotherapy 
with or without anti-EGFR/VEGF-targeted therapy. Fur-
thermore, patients exhibiting synchronized liver metastasis 
were permitted to undergo radiofrequency ablation (RFA) 
and transcatheter arterial chemoembolization (TACE).
The 25 stage IV patients were followed for 33 months. We 
found a significantly increased 24-month survival rate in the 
SLN-T cell immunotherapy group compared to the control 
group: 55.6 vs. 17.5 % (p = 0.02). A tendency of an increased 
OS was observed among patients receiving SLN-T cell transfu-
sion (n = 9, median OS 28 months) compared with the control 
(n = 16, median OS 14 months), although the log-rank test did 
not indicate a significant difference (p = 0.35) (Fig. 3e).
Discussion
In this study, we demonstrate that SLNs are a naturally 
enriched source of tumor-reactive T cells that can be 
Table 3  SLN-T cell transfusion-related toxicity evaluated by CTCAE version 3.0
ALT alanine aminotransferase, AST aspartate transaminase
Grade of 
adverse events
Pre (n = 55) Post (n = 55)
Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%) Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%)
Albumin 9 (16.4) 0 0 0 3 (5.5) 0 0 0
ALT 12 (21.8) 1 (1.8) 0 0 15 (27.3) 0 0 0
AST 15 (27.3) 0 0 0 5 (9.1) 0 0 0
Bilirubin 2 (3.6) 0 0 0 2 (3.6) 0 0 0
Creatinine 54 (98.2) 1 (1.8) 0 0 54 (98.2) 1 (1.8) 0 0
Hemoglobin 20 (36.4) 8 (14.5) 4 (7.3) 0 25 (45.5) 9 (16.4) 1 (1.8) 0
Leukocytes 8 (14.5) 3 (5.5) 0 0 10 (18.2) 1 (1.8) 0 0
Lymphopenia 8 (14.5) 4 (7.3) 0 0 3 (5.5) 2 (3.6) 0 0
Neutrophils 12 (21.8) 8 (14.5) 0 0 7 (12.7) 4 (7.3) 0 0
Platelets 2 (3.6) 0 0 0 3 (5.5) 0 0 0
Allergy 0 0 0 0 0 0 0 0
Nausea 0 0 0 0 0 0 0 0
Vomiting 0 0 0 0 0 0 0 0
Diarrhea 0 0 0 0 0 0 0 0
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primed using autologous tumor antigens without prior 
in vivo vaccination or supplementation of antigens from 
synthesized tumor peptides or tumor cell lines. After pol-
yclonal expansion of tumor-specific CD8+ and CD4+ 
cells, the SLN-T cells can be safely transfused back into 
patients as an adjuvant to current standard treatment regi-
mens for CRC. Our results indicate the promising potential 
for developing SLN-T cell-based immunotherapy for CRC 
patients, especially for the improvement of the long-term 
survival of patients with non-resectable mCRC.
In previous studies, several groups reported in animal 
models that the injection of primary tumor cells induces 
sensitized T cells within the draining lymph nodes local 
to the injection sites. Tumor-reactive T cells from lymph 
nodes can be further expanded ex vivo in the presence of 
an anti-CD3 stimulus with or without CD28 engagement 
in addition to interleukin-2 to treat established tumors [17, 
18, 23–27]. These preclinical studies were further verified 
in two feasibility studies and one phase II study of head 
and neck carcinoma [28], renal cell carcinoma [29, 30] and 
melanoma [30]. The results of these studies indicate that 
this approach induces a tumor-specific immune response 
in the draining lymph node, which is a feasible source of 
tumor-reactive T cells for effective immunotherapy. In 
our study, we demonstrate that SLNs naturally contain 
many more tumor-reactive T cells than the PBL and TILs. 
Without any prior tumor vaccination or additional inva-
sive surgical procedures to obtain the enlarged vaccinated 
lymph node, the SLN-T cell population can be expanded 
reproducibly for immunotherapeutic purposes. The SLN 
is a specialized site at which lymphocytes first encounter 
tumor antigens in association with antigen-presenting cells 
(APCs) and initiate local anti-tumor immune responses. 
We demonstrate that the SLN represents a unique immune 
microenvironment in terms of the lymphocyte population, 
the lymphocyte activation status and the response of lym-
phocytes to autologous tumor antigens. Compared with the 
corresponding PBL or TILs, in the SLNs, the proportions of 
B lymphocytes, CD3+CD4+ and CD4+CD69+ T lympho-
cytes, together with the CD4+/CD8+ ratio, are significantly 
higher; this result reflects the preferable selection of T 
helper cells and B lymphocytes by the SLN microenviron-
ment to enhance tumor antigen-presenting activity and anti-
tumor immune regulation. Moreover, rather than repeatedly 
providing non-specific stimulation with anti-CD3/CD28, 
in our serum-free culture system, specific stimulation with 
autologous tumor antigen is performed during the initial 
and middle phases of culture, resulting in tumor-specific 
polyclonal expansion of CD8+ and CD4+ cells.
Tregs are key mediators in maintaining peripheral tol-
erance and inhibiting anti-tumor immune response within 
the tumor microenvironment. In previous studies, the cor-
relation of the number of CD4+CD25+Foxp3+ Tregs in 
TDLNs with tumor stage and survival was contradic-
tory [31, 32]. The transcription factor Foxp3 has been 
shown to play a crucial role in Treg development, but it 
is not strictly expressed by natural or induced Tregs. In 
this study, staining for the specific surface marker profile 
CD4+CD25+CD127low/− was used to identify Tregs [33, 
34]. We observed a significant elevation of the circulat-
ing CD4+CD25+CD127low/− Treg population in CRC 
patients compared with healthy controls. In both PBL and 
the SLNs, the CD4+CD25+CD127low/− Treg levels did not 
correlate with the disease severity. Moreover, we exam-
ined the circulating CD4+CD25+CD127low/− Treg levels 
at specific time points after surgery and systemic adjuvant 
chemotherapy in three patients with stage III disease. The 
circulating CD4+CD25+CD127low/− Treg levels tended to 
decline post-chemotherapy (Fig. 2d). This finding indicates 
that 5-FU-based cytotoxic chemotherapy can modulate the 
tumor microenvironment to augment anti-tumor immune 
responses. Therefore, a combinatorial approach of chemo-
therapy together with immunotherapy is recommended for 
future studies.
The current successful immunotherapies for cancer 
fall into several broad categories: (1) immune checkpoint 
blockade against inhibitory pathways targeting cytotoxic 
T lymphocyte-associated antigen-4 (CLTA-4) and pro-
grammed cell death protein 1 (PD-1) and its ligand (PD-
L1) [35–37]; (2) cancer vaccines including autologous 
tumor cells, dendritic cells pulsed with specific tumor anti-
gens [38] and several identified tumor peptide antigens [39, 
40]; and (3) adoptive cell transfusion (ACT), including that 
of ex vivo-activated and ex vivo-expanded autologous T 
cells [41, 42] or genetically engineered T cells expressing 
chimeric antigen receptors [43, 44]. The vaccine and ACT 
approaches are the most typically explored immunothera-
pies for CRC. Among these approaches, the best-studied 
tumor vaccine, OncoVAX, consists of irradiated autolo-
gous tumor cells together with the adjuvant BCG. When 
tested in postoperative CRC patients, improvements in 
recurrence-free duration and survival were only observed 
in stage II patients [12]. The most successful ACT-based 
immunotherapy for solid tumors is the transfusion of TILs 
in metastatic melanoma patients [42, 45] together with 
lymph-depletion conditioning and administration of IL-2; 
however, the application of TILs to CRC is limited because 
of the absence of tumor-specific effector cells after ex vivo 
expansion [46]. Therefore, there is a need for a more effec-
tive immunotherapy for CRC. In our study, we demonstrate 
that SLN-T cell-based immunotherapy is feasible for stage 
I–IV CRC patients. Moreover, the transfusion of SLN-T 
cells at doses of up to 639.0 million cells is safe. Evaluat-
ing the clinical efficacy of SLN-T immunotherapy for stage 
IV patients enables the assessment of the survival benefits 
over a limited period. Our results demonstrate that SLN-T 
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cell treatment significantly improved the survival rate of 
stage IV patients. Furthermore, a prolonged median OS 
was observed in the SLN-T immunotherapy group com-
pared with the control group (28 vs. 14 months). However, 
because of the small sample size of this study, statistical 
significance was not reached. Further studies with larger 
sample sizes are warranted to more precisely determine the 
survival effect of SLN-T cell-based immunotherapy. More-
over, in this study, SLN-T cells have been administered in 
the absence of supporting adjuvants or cytokines that may 
enhance the in vivo persistence of transferred T cells. This 
needs to be investigated in future studies. In clinical prac-
tice, most stage IV CRC patients are not candidates for 
surgical resection, eliminating easy access to SLNs and 
autologous tumor cells. Therefore, patients who undergo 
curative resection of hepatic metastases represent the tar-
geted patients for our next study. The potential benefits of 
resection of primary tumors in patients with stage IV CRC 
have been extensively studied [47]. Although the results 
are contradictory, the benefits of primary tumor resection 
should be further addressed. Immunotherapy should be 
added to current therapies to optimize clinical outcomes 
under the conditions of a minimal tumor burden. Moreover, 
the clinically beneficial effects of reducing tumor recur-
rence after surgery must be addressed in stage I–III CRC 
patients.
As a deeper understanding of the human immune 
system and tumor immunology has become available, 
successful immunotherapies against select tumor types 
have continued to be developed. Here, we demonstrate 
a phase I/II study of SLN-T cell-based adjuvant immu-
notherapy in 71 stage I–IV postoperative CRC patients. 
Our results demonstrate that SLN-T cell-based immuno-
therapy is feasible as an adjuvant to the current stand-
ard treatment regimens for CRC. At the dose range of 
20.7–639.0 × 106 total SLN-T cells, this treatment is 
safe. Moreover, this treatment may improve the long-
term survival of non-resectable mCRC patients. Future 
investigations, including randomized control trials, are 
needed to confirm the survival benefit of this immuno-
therapy to stage IV CRC patients and to explore its pos-
sible efficacy in reducing the rate of recurrence in stage 
I–III CRC patients.
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